Financial report for the period January 1, 2022 to September 30, 2022
- Operating profit increased by 28% in Danish kroner and by 14% at constant exchange rates (cc) to DKK 57.7 billion.
- Sales in North American operations increased by 37% in Danish kroner (22% at CER) and sales in international operations increased by 16% in Danish kroner (11% at CER).
- Diabetes and obesity care sales increased by 29% in Danish kroner to 113.2 billion DKK (18% at CER), mainly due to sales growth of GLP-1 diabetes of 59% in Danish kroner (44% up CER) was due. Rare disease sales increased by 8% measured in Danish kroner (2% at CER).
- Bariatric care sales increased by 91% in Danish kroner (75% at CER). Novo Nordisk expects to make all Wegovy® Dose strengths available in the US towards the end of 2022.
- In terms of R&D, Novo Nordisk successfully completed a phase 2 study of CagriSema in people with type 2 diabetes and the final phase 3a study of insulin icodec once a week.
- For the 2022 outlook, revenue growth of 14-17% at CER and operating profit growth of 13-16% at CER are now expected. Revenue and operating profit growth, as reported in Danish kroner, is now expected to be 10 and 15 percentage points higher than in CER, respectively.
| WIN AND LOSS | 9M 2022 | 9M 2021 | growth as reported |
growth at CER* |
| million DKK | ||||
| net sales | 128,862 | 102,467 | 26% | 16% |
| operating result | … |
